Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Medicine (Baltimore) ; 102(40): e34804, 2023 Oct 06.
Article in English | MEDLINE | ID: mdl-37800765

ABSTRACT

BACKGROUND: Being overweight or obese is closely related to adverse pregnancy outcomes and harms both pregnant women and neonates, increasing complications during pregnancy and leading to adverse pregnancy outcomes. Consequently, a meta-analysis was done to investigate exercise therapy impact on the complications and outcomes of pregnant women who are obese or overweight. MATERIALS AND METHODS: The computer system searched PubMed, Cochrane Library, Wanfang, EMBASE, and CNKI databases. The search duration extended from the database establishment until October 2022. A thorough search was carried out for pertinent studies investigating exercise therapy impact on pregnancy complications and outcomes in obese or overweight pregnant women. The heterogeneity test was carried out using Cochrane Q and Chi-square tests. The combined findings from the meta-analysis were examined for reliability and robustness using sensitivity and publication bias analyses. All statistics used RevMan 5.3 software. RESULTS: This meta-analysis included data from 8026 patients from 22 randomized controlled trials. The results demonstrated that exercise therapy might successfully decrease the incidence of gestational diabetes mellitus (GDM) (odds ratio [OR] = 0.85, 95% confidence interval [CI]: 0.74-0.96, P = .01) and macrosomia (OR = 0.78, 95% CI: 0.68-0.89, P < .001), and control weight gain during pregnancy (SMD = -0.2, 95% CI: -0.31 to -0.08, P < .001). CONCLUSIONS: Exercise therapy can control weight gain during pregnancy, lower the incidence of GDM and the macrosomia rate, and improve adverse pregnancy outcomes.


Subject(s)
Diabetes, Gestational , Pregnancy Complications , Infant, Newborn , Female , Humans , Pregnancy , Overweight/complications , Overweight/therapy , Pregnancy Outcome/epidemiology , Pregnant Women , Fetal Macrosomia , Reproducibility of Results , Exercise , Obesity/complications , Obesity/therapy , Obesity/epidemiology , Weight Gain , Pregnancy Complications/therapy , Pregnancy Complications/epidemiology , Exercise Therapy
2.
Front Oncol ; 12: 918693, 2022.
Article in English | MEDLINE | ID: mdl-35814398

ABSTRACT

Objective: To study the oncological safety of diagnostic hysteroscopy for women with apparent early-stage type II endometrial cancer. Patients and Methods: A total of 429 women with presumed early-stage type II endometrial cancer were included. The 5-year disease-free survival (DFS) and overall survival (OS) were estimated and compared using the Kaplan-Meier method and the log-rank test among patients diagnosed by Dilation & Curettage (D&C) or diagnostic hysteroscopy. The Cox proportional hazards regression model was employed to adjust for potential confounding factors. Results: 160 cases underwent D&C and 269 cases were diagnosed by diagnostic hysteroscopy. The 5-year DFS rate was 72.17% in the diagnostic hysteroscopy group and 76.16% in the D&C group, diagnostic hysteroscopy was not associated with deteriorated 5-year DFS rate (HR 1.25, 95% CI 0.84-1.86, P=0.281). The 5-year OS rate was 67.23% in the diagnostic hysteroscopy group and 70.71% in the D&C group, diagnostic hysteroscopy did not increase the risk of all-cause death (HR 1.11, 95% CI 0.78-1.57, P=0.573). Multivariable analysis showed that the method of endometrial sampling was not independently associated with DFS (aHR 1.38, 95% CI 0.92-2.07, P=0.122) and OS (aHR 1.23, 95% CI 0.85-1.77, P=0.272). Conclusion: For apparent early-stage type II endometrial cancer, endometrial sampling by diagnostic hysteroscopy was as safe as D&C.

3.
BMJ Open ; 12(7): e056848, 2022 07 29.
Article in English | MEDLINE | ID: mdl-35906063

ABSTRACT

INTRODUCTION: The management of women with clinical early-stage cervical cancer and lymph node involvement detected intraoperatively is heterogeneous and controversial. This paper presents the protocol of a systematic review and meta-analysis regarding the management of this specific population of patients. This proposed study aims to answer the question: does completion of radical hysterectomy improve the oncological outcomes of women with clinical early-stage cervical cancer and intraoperatively detected nodal involvement? METHODS AND ANALYSIS: This protocol is drafted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines, and the proposed study will be conducted in accordance with the standard guidelines of 'Preferred Reporting Items for Systematic Reviews and Meta-Analyses' and 'Meta-analysis of Observational Studies in Epidemiology reporting guideline'. Comprehensive literature searches will be performed in PubMed, Embase, Scopus, and Web of Science. The screening of the eligible studies, the extraction of data of interest, and the quality assessment of the included studies will all be independently performed by different members of our team. The primary outcome of this proposed study will be comparing the risk of recurrence or death from cervical cancer and the risk of all-cause death in patients with two different treatments (completion of radical hysterectomy or abandonment of radical hysterectomy); the secondary outcome of this proposed study will be comparing the risk of the grade 3/4 toxicities associated with the two types of management. Given the clinical heterogeneity among the included studies, data on outcomes will be pooled by random-effects models. Heterogeneity will be evaluated using the I2 statistic. The risk of bias for the included studies will be evaluated using the Newcastle-Ottawa Scale or the Cochrane collaboration's tool. The grade of evidence will be evaluated by two independent members of our team using the Grading of Recommendations, Assessment, Development and Evaluations approach. ETHICS AND DISSEMINATION: Ethical approval is not required because there will no primary data collected. The findings of this proposed study will be published in an international peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42021273527.


Subject(s)
Uterine Cervical Neoplasms , Female , Humans , Hysterectomy , Lymph Nodes , Meta-Analysis as Topic , Observational Studies as Topic , Research Design , Systematic Reviews as Topic , Uterine Cervical Neoplasms/surgery
4.
Front Oncol ; 12: 800957, 2022.
Article in English | MEDLINE | ID: mdl-35402252

ABSTRACT

Objective: The survival value of systematic lymphadenectomy for endometrial cancer is ambiguous and controversial. The current study aimed to evaluate the long-term survival role of combined pelvic and para-aortic lymphadenectomy in patients with presumed early-stage clear cell carcinoma of the endometrium. Methods: Patients in three Chinese teaching hospitals who presented between 2012 and 2017 with apparent early-stage clear cell carcinoma of the endometrium and underwent surgical staging were selected. Patients who did and did not undergo systematic lymphadenectomy were identified and clinicopathological characteristics were compared. Disease-free survival and overall survival were evaluated following the generation of the Kaplan-Meier curves and the comparison using the log-rank test. A Cox proportional hazards model was employed to control for confounders. Results: A total of 244 patients underwent systematic lymphadenectomy and 89 did not receive lymph node dissection. The demographic and baseline data were comparable between the two groups. The rate of disease-free survival at 5 years was 64.10% in patients who underwent systematic lymphadenectomy and 45.05% in patients who did not undergo lymphadenectomy. Patients who underwent systematic lymphadenectomy had better disease-free survival than those who did not receive lymphadenectomy (HR, 0.54. 95% CI, 0.38-0.76. P=0.000). The rate of 5-year overall survival was 68.87% in the lymphadenectomy group and 53.33% in patients who did not undergo systematic lymphadenectomy. Systematic lymphadenectomy was also associated with improved 5-year overall survival for women with presumed early-stage clear cell carcinoma of the endometrium (HR, 0.58. 95% CI, 0.39-0.85. P=0.005). After adjusting for confounders, systematic lymphadenectomy was still independently associated with improved disease-free survival and overall survival. Conclusion: Patients with apparent early-stage clear cell carcinoma of the endometrium who underwent systematic lymphadenectomy had better long-term survival than those who did not undergo systematic lymphadenectomy.

5.
Int J Gen Med ; 14: 9945-9950, 2021.
Article in English | MEDLINE | ID: mdl-34938112

ABSTRACT

PURPOSE: The global incidence of gestational diabetes mellitus (GDM) is increasing year by year, and many studies have proved that long non-coding RNA (lncRNA) is involved in the regulation of GDM. The purpose of this study was to investigate the expression of HOTAIR in GDM patients and its clinical significance. PATIENTS AND METHODS: Ninety-eight healthy pregnant women and 99 pregnant women diagnosed with GDM were enrolled in this study. Blood samples were collected from all participants and used for qRT-PCR analysis to determine the serum HOTAIR levels. The ROC curve was constructed to evaluate the diagnostic value of HOTAIR for GDM. Pearson correlation coefficient was used to estimate the correlation between HOTAIR and clinical indicators of patients. Logistic regression analysis was performed to evaluate the independent predictors of GDM. RESULTS: The level of HOTAIR was augmented in GDM group compared with healthy controls. ROC curve revealed that HOTAIR as a diagnostic marker of GDM has high sensitivity and specificity. Pearson correlation coefficient showed that HOTAIR level was positively correlated with body mass index, fasting plasma glucose, 1-hour plasma glucose and 2-hour plasma glucose. Logistic regression analysis shows that HOTAIR is an independent factor of the occurrence of GDM. CONCLUSION: The abnormal expression of HOTAIR in pregnant women with GDM made it a potential diagnostic biomarker for GDM.

6.
J BUON ; 26(4): 1320-1326, 2021.
Article in English | MEDLINE | ID: mdl-34564987

ABSTRACT

PURPOSE: To explore the clinical efficacy of hysteroscopic resection combined with megestrol acetate in the treatment of patients with early-stage endometrial cancer (EC) and its prognosis. METHODS: 130 patients with early-stage EC were divided into two groups: MA group (hysteroscopic resection combined with megestrol acetate, n=65) and Control group (hysteroscopic resection alone, n=65). The clinical efficacy, serum carbohydrate antigen 125 (CA125) level and incidence of adverse reactions were compared between the two groups, and the patients' pregnancy status, pregnancy outcome, survival status and tumor recurrence were recorded through follow-up. RESULTS: The curative effect was assessed in all patients after treatment. The overall response rate was 83.1% (54/65) and 65.2% (43/65), respectively, in MA group and Control group, which was significant better in MA group than that in Control group. After treatment, the serum CA125 levels markedly declined in both groups. The pregnancy rate in MA group was obviously higher than in Control group. The follow-up results revealed that the 5-year overall survival (OS) was 83.1% (54/65) and 81.5% (53/65) and the progression-free survival (PFS) was 76.9% (50/65) and 73.8% (48/65), respectively, in MA group and Control group. CONCLUSION: Hysteroscopic resection combined with megestrol acetate has superior clinical efficacy to hysteroscopic resection alone in the treatment of patients with early-stage EC, which can greatly increase the success rate of pregnancy and reduce the serum CA125 level. However, thelong-term survival and PFS of patients had no significant differencesbetween the two treatment methods. Key words: hysteroscopic resection, megestrol acetate, endometrial cancer, early stage, curative effect.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Carcinoma, Endometrioid/drug therapy , Carcinoma, Endometrioid/surgery , Endometrial Neoplasms/drug therapy , Endometrial Neoplasms/surgery , Hysteroscopy , Megestrol Acetate/therapeutic use , Progesterone/therapeutic use , Adult , Carcinoma, Endometrioid/pathology , Combined Modality Therapy , Endometrial Neoplasms/pathology , Female , Humans , Neoplasm Staging , Prognosis , Retrospective Studies , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...